Sign Up to like & get recommendations! 1
Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.13180
Abstract: Key Points Question Is gestational age at initiation of chemotherapy during pregnancy associated with risk of congenital malformations? Findings In this cohort study including 755 pregnant women with cancer, the risk of major congenital malformations… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.13533
Abstract: Key Points Question Is cumulative social risk (ie, co-occurring sociodemographic barriers) associated with lower receipt of chemotherapy among patients with advanced colorectal cancer, and does social support moderate this association? Findings Data from a cross-sectional… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.18603
Abstract: This cohort study evaluates the overall survival for patients with uterine cancer with distant organ metastasis treated with chemotherapy alone vs chemotherapy plus total abdominal hysterectomy. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.45515
Abstract: Key Points Question What are the comparative short-term and long-term outcomes associated with first-line chemotherapy regimens for patients with metastatic pancreatic cancer, and how do they compare with chemotherapy regimens recommended in Japanese guidelines? Findings… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.46912
Abstract: This cohort study examines the use and outcomes associated with neoadjuvant and adjuvant chemotherapy vs surgery alone in patients with resectable gallbladder cancer. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.0602
Abstract: This cross-sectional study examines the use of intravesical chemotherapy after transurethral resection of bladder tumor before and after publication of a randomized clinical trial showing the benefits of intravesical chemotherapy. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.1855
Abstract: Importance The variability in individual symptom and adverse event reporting between pediatric patient-reports and proxy-reports is widely reported. However, the question of whether symptom profiles based on reports from children with cancer and their caregivers… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.10894
Abstract: This secondary analysis of the J-FORCE randomized clinical trial examines the effect of olanzapine plus triplet antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with a malignant tumor, stratified by 6 risk factors. read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.16161
Abstract: Key Points Question Is fluoropyrimidine-based systemic chemotherapy effective in treating patients with inoperable low-grade mucinous appendiceal adenocarcinoma? Findings In this randomized crossover trial that included 24 patients, there was no significant difference in tumor growth… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.4254
Abstract: Key Points Question Is antibiotic therapy associated with response to chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)? Findings In this cohort study of 3850 older adults with metastatic PDAC, receipt of perichemotherapy antibiotics… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2016.2530
Abstract: Importance Antiemetics are used to prevent chemotherapy-induced nausea and vomiting in patients with cancer. Newer antiemetic agents (serotonin and neurokinin-1 receptor antagonists) have increased efficacy but are expensive. The American Society of Clinical Oncology’s first… read more here.